(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/016806 A1

(51) **International Patent Classification**:
A61K 31/7105 (2006.01) *A61K 31/711* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)

(21) **International Application Number**:
PCT/SG2009/000276

(22) **International Filing Date**:
7 August 2009 (07.08.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
PCT/SG2008/000294 8 August 2008 (08.08.2008) SG
200901445-7 18 February 2009 (18.02.2009) SG

(71) **Applicant** *(for all designated States except US)*: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).

(72) **Inventor; and**
(75) **Inventor/Applicant** *(for US only)*: **ZENG, Qi** [SG/SG]; Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG).

(74) **Agent**: **KHOO, Chong, Yee**; Cantab LLP, VBox 881846, Singapore 919191 (SG).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: VHZ FOR DIAGNOSIS AND TREATMENT OF CANCERS

FIGURE 1A



(57) **Abstract**: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.

WO 2010/016806 A1